Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI0618 MAD study in healthy volunteers
NCT05714254Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2022
- Primary completion
- Dec 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic pain comparing MEDI0618 with Placebo (2 arms). Primary endpoints: Incidence of adverse events, Incidence of abnormal vital signs and 1 more. Started Dec 2022; status: completed.
02
Drugs
MEDI0618
03
Conditions
chronic pain
Beyond the preview
Go deeper on NCT05714254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05714254.